| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2021-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97ef211f996009dbc6843852fc5460d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc9a23aa37aef19cd7c48477b4cf125d |
| publicationDate |
2022-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115025223-A |
| titleOfInvention |
A delivery protein of SETD4 protein inhibitor for activating dormant tumor cells |
| abstract |
The present invention discloses a delivery protein of a SETD4 protein inhibitor for activating dormant tumor cells. The SETD4 protein inhibitor includes DEK protein, and the DEK protein has a conserved region shown in SEQ ID NO.25. The invention provides a SETD4 protein inhibitor, in particular the application of DEK protein in activating dormant tumor cells, removing tumor cells and curing tumors. Cancer patients can be directed to transfer DEK gene or deliver DEK in quiescent tumor cells at different stages. The protein can activate resting tumor cells and make them lose their resistance to tumor therapy. In vitro experiments have verified that the clearance rate of resting cells in clinical breast cancer patients is 100%. Combined with standard radiotherapy and chemotherapy treatment, dormant tumor cells can be completely eliminated, so as to achieve the curative treatment of various human cancers and prevent tumor recurrence. |
| priorityDate |
2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |